# Clinical Context for Cutpoint Selection

## Trial: KEYNOTE-024
**Indication:** First-line metastatic NSCLC, PD-L1 â‰¥50%

---

## Progression-Free Survival (Key Clinical Anchor)

### Pembrolizumab
- **Median PFS:** 10.3 months (95% CI: 6.7 - NR)
- **Interpretation:** Long tail driven by durable responders

### Chemotherapy
- **Median PFS:** 6.0 months (95% CI: 4.2 - 6.2)
- **Interpretation:** Typical platinum doublet PFS

**Hazard Ratio:** 0.50 (95% CI: 0.37-0.68, p<0.001)

---

## Treatment Crossover

**Protocol:** Chemotherapy patients with verified disease progression could 
cross over to receive pembrolizumab.

**Actual Crossover:**
- **N crossed over:** 66/151 (43.7%)
- **Timing:** Predominantly 6-9 months (around median PFS)
- **Impact:** Creates structural break in chemotherapy OS hazard post-progression

---

## Treatment Mechanisms (Biological Context)

### Chemotherapy (Platinum-Based)
- **Mechanism:** Immediate cytotoxic effect
- **Expected hazard:** Relatively constant until progression
- **Post-progression:** Hazard changes due to crossover effect

### Pembrolizumab (PD-1 Inhibitor)
- **Mechanism:** Delayed immune response, responder/non-responder separation
- **Expected hazard:** High early (non-responders), then plateau (responders)
- **Characteristic:** Hazard approaches zero in durable responders

---

## Protocol Context

**Imaging Schedule:** Every 9 weeks per protocol (Weeks 9, 18, 27, 36, 45...)